People with blood cancer to benefit from innovative new treatment on the NHS The type of Car T-cell therapy involves taking a patient’s T-cells and modifying them. Evening Standard · Feb 20, 2025
Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks. Barchart · Jan 10, 2025
Why This Dividend Stock Just Scored a Rare Upgrade Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships. Barchart · Dec 24, 2024
New schizophrenia drug ‘could change the lives of millions of people’ The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb. The Independent UK · Sep 27, 2024
Cobenfy Gets FDA Approval: New Drug Offers Novel Treatment Mechanism For Schizophrenia The new drug Cobenfy promises to revolutionize treatment for schizophrenia with its novel mechanism, the first of its kind in decades. Medical Daily · Sep 27, 2024
$100-million facility of Bristol Myers Squibb opened in Hyderabad Bristol Myers Squibb opens new facility in Hyderabad, investing over $100 million to expand global capabilities. The Hindu · Feb 26, 2024
Bristol Myers Squibb Reports Strong Q4 Results Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential. Top News · Feb 21, 2024
Senators ask CEOs why their drugs cost so much more in the U.S. The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe. WEKU · Feb 8, 2024
Merck, Johnson & Johnson CEOs agree to appear before Senate HELP - Roll Call Two drug company CEOs have agreed to testify before the Senate HELP Committee on drug prices, avoiding a scheduled subpoena vote on Jan. 31. Roll Call · Jan 26, 2024
Nasdaq Posts a Record High on Strength in Chip Stocks What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.60%. Stocks on Tuesday settled moderately higher, with the... Barchart · Dec 26, 2023
Stocks Climb on Strength in Chip Stocks and Energy Companies What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.42%. Stocks this morning are moderately higher in thin holiday... Barchart · Dec 26, 2023
Markets Today: Stocks Modestly Higher in Thin Holiday Trade Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.09%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.15%. Stock index futures this morning are modestly higher in thin holiday trade, with markets in Europe and parts of Asia closed for Boxing Day. Stocks are supported... Barchart · Dec 26, 2023
Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru... Top News · Dec 22, 2023
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal The Independent UK · Dec 22, 2023
Fortune · Nov 13, 2023 Developing new medicines for everyone, everywhere, equally The pharmaceutical industry’s role as healer is sorely diminished if we don’t develop medicines fairly for everyone who needs them.
The Guardian - US · Aug 29, 2023 Biden names 10 drugs for first negotiations to cut Medicare prices Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional
Fortune · Jun 9, 2023 Rethinking auditing and transparency in the age of A.I. In today’s world of increasing disclosures, such as ESG and cybersecurity, the responsibility of the internal audit continues to expand and has become even more critical.
Fortune · Apr 28, 2023 How health care leaders are leveraging technology in a tumultuous economy Making health care accessible and equitable is the goal.
Fortune · Apr 26, 2023 3 factors driving health care inequality—and ideas for how we can solve it 'The rich get richer, and the poor get poorer. The same is true for health...The underserved get sicker.'
Benzinga · Aug 23, 2022 Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…
Benzinga · Aug 10, 2022 Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…
Benzinga · Jul 29, 2022 Recap Of Friday's Biotech Catalysts - End of The Day Summary The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…
Benzinga · Jul 22, 2022 Recap Of Friday's Biotech Catalysts - End Of The Day Summary Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…
Fortune · Jul 21, 2022 'ESG' represents a fundamental shift in business strategy—but the term is unclear, unpopular, and increasingly polarizing "Women's and family health has always been underserved," says Ryder.
Benzinga · Jun 6, 2022 Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX) Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to…